Form 4: Bionano Genomics Director Hannah Mamuszka Granted Stock Options

Bionano Genomics, Inc. director Hannah Mamuszka was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months or upon the next annual stockholder meeting.

Summary

• Hannah Mamuszka, a Director of Bionano Genomics, Inc. (BNGO), was granted 2,775 stock options.
• The options have an exercise price of $3.67 per share.
• The grant date for these options was June 11, 2025.
• The options will expire on June 10, 2035.
• Vesting occurs in equal monthly installments over 12 months from the grant date.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to continuous service.
• Full vesting will also occur upon a Change of Control of the company.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns interests. It's not a significant positive or negative for the company's operational performance, but rather a standard governance practice.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedule, tied to continuous service and a change of control clause, provides stability and potential accelerated benefits under specific corporate events.

Negatives

• The exercise price of $3.67 is the current market price at the time of grant, meaning the options only have intrinsic value if the stock price increases above this level.
• The options represent potential dilution if exercised in the future, though the number of shares is relatively small.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing. The inherent risk is that the stock price may not exceed the exercise price, rendering the options worthless.

Industry Context

This Form 4 filing details an individual director's equity compensation, which is a standard practice across industries to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director (Hannah Mamuszka) constitutes a related party transaction, as directors are considered related parties to the company.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, it also represents potential future dilution if options are exercised.
• Employees: No direct impact on general employees mentioned.

Next Steps

• The options will vest in equal monthly installments over the 12 months following the grant date.
• The options will fully vest on the date of the Company's next annual stockholder meeting.

Key Dates

Keywords

Bionano Genomics, BNGO, SEC Form 4, Stock Options, Director Compensation, Equity Grant, Hannah Mamuszka, Insider Transaction, Vesting Schedule